Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series

2019 ◽  
Vol 17 (3) ◽  
pp. 393-397 ◽  
Author(s):  
Bryan Garcia ◽  
◽  
Nirmal Sharma ◽  
Kevin Johnson ◽  
Juan Salgado ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals COVID-19 Disease in Lung Transplant Recipients: A Case Series

2021 ◽  
Vol 40 (4) ◽  
pp. S314
Author(s):  
L.L. Seijo ◽  
A. Perez ◽  
N. Thakur ◽  
A. Venado ◽  
L.E. Leard ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19

2021 ◽  
Vol 2 (2) ◽  
pp. 229-245
Author(s):  
René Hage ◽  
Carolin Steinack ◽  
Fiorenza Gautschi ◽  
Susan Pfister ◽  
Ilhan Inci ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Clinical Laboratory ◽  
Invasive Mechanical Ventilation ◽  
Case Series ◽  
Outcome Data ◽  
Transplant Recipients ◽  
Retrospective Case ◽  
Laboratory Findings ◽  
Case Series Study ◽  
Lung Transplant Recipients

We report clinical features, treatments and outcomes in 18 lung transplant recipients with laboratory confirmed SARS-CoV-2 infection. We performed a single center, retrospective case series study of lung transplant recipients, who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 2021. Clinical, laboratory and radiology findingswere obtained. Treatment regimens and patient outcome data were obtained by reviewing the electronic medical record. Mean age was 49.9 (22–68) years, and twelve (67%) patients were male. The most common symptoms were fever (n = 9, 50%), nausea/vomiting (n = 7, 39%), cough (n = 6, 33%), dyspnea (n = 6, 33%) and fatigue (n = 6, 33%). Headache was reported by five patients (28%). The most notable laboratory findings were elevated levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). Computed Tomography (CT) of the chest was performed in all hospitalized patients (n = 11, 7%), and showed ground-glass opacities (GGO) in 11 patients (100%), of whom nine (82%) had GGO combined with pulmonary consolidations. Six (33%) patients received remdesivir, five (28%) intravenous dexamethasone either alone or in combination with remdesivir, and 15 (83%) were treated with broad spectrum antibiotics including co-amoxicillin, tazobactam-piperacillin and meropenem. Four (22%) patients were transferred to the intensive care unit, two patients (11%) required invasive mechanical ventilation who could not be successfully extubated and died. Eighty-nine percent of our patients survived COVID-19 and were cured. Two patients with severe COVID-19 did not survive.

scholarly journals COVID‐19 in lung transplant recipients: A case series from Milan, Italy

2020 ◽  
Vol 22 (6) ◽  
Author(s):  
Letizia Corinna Morlacchi ◽  
Valeria Rossetti ◽  
Lorenzo Gigli ◽  
Francesco Amati ◽  
Lorenzo Rosso ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Hepatitis E Virus Infection in Lung Transplant Recipients: A Case Series

2019 ◽  
Vol 51 (2) ◽  
pp. 376-379 ◽  
Author(s):  
G.P.L. Ambrocio ◽  
S. Aguado ◽  
J. Carrillo ◽  
R. Laporta ◽  
M. Lazaro-Carrasco ◽  
...  
Keyword(s):  
Virus Infection ◽  
Lung Transplant ◽  
Hepatitis E Virus ◽  
Case Series ◽  
Hepatitis E ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Carbapenem-resistantKlebsiella pneumoniaein lung transplant recipients: A case series

2015 ◽  
Author(s):  
Priscila Cilene León Bueno Camargo ◽  
Silvia Vidal Campos ◽  
Felipe Xavier Melo ◽  
Ricardo Henrique de Oliveira Braga Teixeira ◽  
Paulo Manuel Pêgo-Fernandes
Keyword(s):  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature

2017 ◽  
Vol 32 (2) ◽  
pp. e13176 ◽  
Author(s):  
Jose Tiago Silva ◽  
Virginia Pérez-González ◽  
Francisco Lopez-Medrano ◽  
Rodrigo Alonso-Moralejo ◽  
Mario Fernández-Ruiz ◽  
...  
Keyword(s):  
Cytomegalovirus Infection ◽  
Lung Transplant ◽  
Case Series ◽  
Secondary Prophylaxis ◽  
Transplant Recipients ◽  
Review Of The Literature ◽  
Lung Transplant Recipients

scholarly journals Squamous cell carcinoma of the skin and voriconazole therapy in lung transplant recipients: a case series

2017 ◽  
Vol 47 (3) ◽  
pp. 228-235 ◽  
Author(s):  
Chin Fen Neoh ◽  
Gregory I. Snell ◽  
Bronwyn Levvey ◽  
Catherine Orla Morrissey ◽  
Monica A. Slavin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

Depression, Immunosuppressant Levels, and Clinical Outcomes in Postlung Transplant Recipients

2020 ◽  
Vol 55 (6) ◽  
pp. 421-436 ◽  
Author(s):  
Michael C Chu ◽  
Patrick J Smith ◽  
John M Reynolds ◽  
Scott M Palmer ◽  
Laurie D Snyder ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Lung Transplant ◽  
Epidemiological Studies ◽  
Hazard Ratio ◽  
Adverse Outcomes ◽  
Consecutive Series ◽  
Transplant Recipients ◽  
Increased Risk ◽  
Coefficient Of Variability ◽  
Lung Transplant Recipients

Objective Posttransplant depression has been linked to increased risk for adverse outcomes in lung transplant patients. Maintaining target serum immunosuppressant levels is also essential for optimal lung transplant clinical outcome and may be a crucial predictor of outcomes. Because depression could affect medication nonadherence, resulting in out-of-range immunosuppressant levels, we examined the relationship between posttransplant depression, immunosuppressant medication trough level variability, indexed by out-of-range values on clinical outcomes and coefficient of variability, and clinical outcomes. Method A consecutive series of 236 lung transplant recipients completed the Center for Epidemiological Studies-Depression two-month posttransplant. Immunosuppressant trough levels (i.e., tacrolimus or cyclosporine) within the range of individualized immunosuppressant targets were obtained at three-, six-, nine-month follow-up clinic visits. Clinical outcomes including hospitalizations and mortality were obtained from medical records. Results Fourteen percent of patients were classified as depressed (Center for Epidemiological Studies-Depression ≥16), 144 (61%) of patients had at least 25% out-of-range immunosuppressant values, and the average coefficient of variability was 36%. Over a median of 2.6 years (interquartile range = 1.2), 32 participants died (14%) and 144 (61%) had at least one unplanned, transplant-related hospitalization. Both depression (hazard ratio = 1.45 (1.19, 1.76), p < . 01) and immunosuppressant variation (immunosuppressant out-of-range: hazard ratio = 1.41 (1.10, 1.81), p < .01) independently predicted more frequent hospitalizations and higher mortality. Conclusions Early posttransplant depression was associated with significantly worse clinical outcomes. While immunosuppressant level variability is also related to adverse outcomes, such variability does not account for increased risk observed with depression.

Sign in / Sign up

Export Citation Format

Share Document